EP0655924A4 - A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING. - Google Patents

A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING.

Info

Publication number
EP0655924A4
EP0655924A4 EP93906955A EP93906955A EP0655924A4 EP 0655924 A4 EP0655924 A4 EP 0655924A4 EP 93906955 A EP93906955 A EP 93906955A EP 93906955 A EP93906955 A EP 93906955A EP 0655924 A4 EP0655924 A4 EP 0655924A4
Authority
EP
European Patent Office
Prior art keywords
erbb
combination
monoclonal antibodies
monoclonal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93906955A
Other languages
German (de)
French (fr)
Other versions
EP0655924A1 (en
Inventor
Philip G Kasprzyk
Charles R King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncologix Inc
Original Assignee
Oncologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncologix Inc filed Critical Oncologix Inc
Publication of EP0655924A1 publication Critical patent/EP0655924A1/en
Publication of EP0655924A4 publication Critical patent/EP0655924A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP93906955A 1992-06-30 1992-10-21 A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING. Withdrawn EP0655924A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90655592A 1992-06-30 1992-06-30
US906555 1992-06-30
PCT/US1992/008545 WO1994000136A1 (en) 1992-06-30 1992-10-21 A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING

Publications (2)

Publication Number Publication Date
EP0655924A1 EP0655924A1 (en) 1995-06-07
EP0655924A4 true EP0655924A4 (en) 1996-09-11

Family

ID=25422648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93906955A Withdrawn EP0655924A4 (en) 1992-06-30 1992-10-21 A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING.

Country Status (6)

Country Link
EP (1) EP0655924A4 (en)
JP (1) JPH08504172A (en)
KR (1) KR100269879B1 (en)
AU (1) AU687346B2 (en)
CA (1) CA2120745A1 (en)
WO (1) WO1994000136A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733752B1 (en) 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1191944A2 (en) 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
TR200200472T2 (en) 1999-08-27 2002-06-21 Genentech, Inc. Dosages for treatment with anti-Erb B2 antibodies
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1275398A4 (en) * 2000-04-06 2004-09-01 Kyowa Hakko Kogyo Kk DIAGNOSTICS AND REMEDIES AGAINST RHUMATOID POLYARTHRITIS
CN101289511A (en) 2000-04-11 2008-10-22 杰南技术公司 Multivalent antibodies and uses therefore
KR20130056201A (en) 2000-05-19 2013-05-29 제넨테크, 인크. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
ES2392525T3 (en) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Cancer treatment with the antibody directed against ErbB2 rhuMAb 2C4
CN100408097C (en) * 2002-10-10 2008-08-06 默克专利有限公司 Bispecific anti-ERB-B antibody and its use in tumor therapy
ES2533963T3 (en) * 2002-10-10 2015-04-16 Merck Patent Gmbh Pharmaceutical compositions targeting Erb-B1 receptors
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
JP4969440B2 (en) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， ErbB antagonist for the treatment of pain
KR20120064120A (en) 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
KR20140032004A (en) 2004-07-22 2014-03-13 제넨테크, 인크. Her2 antibody composition
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
EP2054444B1 (en) 2006-08-04 2016-11-02 MedImmune Limited Antibodies to erbb2
CN101675075B (en) 2007-03-01 2014-06-18 西福根有限公司 Recombinant anti-epidermal growth factor receptor antibody compositions
MX2009008981A (en) 2007-03-02 2009-09-02 Genentech Inc Predicting response to a her inhibitor.
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR20190140090A (en) 2007-07-09 2019-12-18 제넨테크, 인크. Prevention of disulfide bond reduction during recombinant production of polypeptides
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN104059955A (en) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 Production Of Proteins In Glutamine-free Cell Culture Media
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
KR20130108069A (en) 2010-04-15 2013-10-02 알퍼 바이오테크, 엘엘씨 Monoclonal antibodies against her2 antigens, and uses therefor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
KR101574864B1 (en) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 Isoform enriched antibody preparation and method for obtaining it
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
SG2014011316A (en) 2011-08-31 2014-06-27 Genentech Inc Diagnostic markers
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
KR102291355B1 (en) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Identification of patients in need of pd-l1 inhibitor cotherapy
KR101453462B1 (en) 2013-05-16 2014-10-23 앱클론(주) Antibodies Capable of Binding Specifically to HER2
MX2016012830A (en) 2014-04-11 2017-01-05 Medimmune Llc Bispecific her2 antibodies.
RU2689145C2 (en) 2014-04-16 2019-05-24 Биокон Лтд. Stable protein preparations containing molar excess of sorbitol
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CN107787331B (en) 2015-06-17 2022-01-11 豪夫迈·罗氏有限公司 anti-HER 2 antibodies and methods of use
WO2018124766A2 (en) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 Chimeric antigen receptor and natural killer cells expressing same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
US12209131B2 (en) 2018-08-16 2025-01-28 Cantargia Ab Anti-IL1RAP antibody compositions
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
GB202309703D0 (en) 2023-06-27 2023-08-09 Epsilogen Ltd Composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (en) * 1988-02-26 1989-09-06 Neorx Corporation Functionally specific antibodies
WO1991005264A1 (en) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (en) * 1988-02-26 1989-09-06 Neorx Corporation Functionally specific antibodies
WO1991005264A1 (en) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KASPRZYK ET AL: "THERAPY OF AN ANIMAL MODEL OF HUMAN GASTRIC CANCER USING A COMBINATION OF ANTI-ERBB-2 MONOCLONAL ANTIBODIES", CANCER RESEARCH, vol. 52, 15 May 1992 (1992-05-15), pages 2771 - 2776, XP002014292 *
See also references of WO9400136A1 *

Also Published As

Publication number Publication date
EP0655924A1 (en) 1995-06-07
AU3773393A (en) 1994-01-24
WO1994000136A1 (en) 1994-01-06
KR950700075A (en) 1995-01-16
JPH08504172A (en) 1996-05-07
CA2120745A1 (en) 1994-01-06
KR100269879B1 (en) 2000-10-16
AU687346B2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
EP0655924A4 (en) A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING.
HU9601574D0 (en) Humanized antibodies and uses thereof
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
AU4289496A (en) Method of promoting an immune response with a bispecific antibody
AU4618193A (en) Humanized antibodies
NZ230786A (en) A method of reducing the heterogeneity of secreted monoclonal antibodies
AU6080794A (en) Antibodies directed against binding-associated epitopes
EP0578515A3 (en) Humanized monoclonal antibodies.
GB9608626D0 (en) Hepatitis b monoclonal antibodies
GB9412166D0 (en) Retargetting antibodies
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
EP0506523A3 (en) Monoclonal antibodies
EP0909278A4 (en) Nephropathy-related immunoglobulin g and antibodies for same
EP0218587A4 (en) Monoclonal antibodies and method of immunizing therewith.
ZA89258B (en) Monoclonal antibodies
AU9143991A (en) Monoclonal antibody op-g2 and method of use
EP0582450A3 (en) Anti-oxytocin receptor antibodies and methods for their production.
EP0654532A4 (en) Antimucoglycoprotein monoclonal antibody.
GB8820036D0 (en) Monoclonal antibodies
EP0468056A4 (en) Anti-procollagenase monoclonal antibodies and a method for the assay of procollagenase utilizing thereof
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0520436A3 (en) Monoclonal antibody, method of production thereof and use thereof
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype
SG64332A1 (en) Monoclonal antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 35/14

RHK1 Main classification (correction)

Ipc: C12N 15/13

A4 Supplementary search report drawn up and despatched

Effective date: 19960726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 20000712

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010123